The purpose of this project is to partner with existing domestic large-scale commercial mRNA vaccine producer(s) with existing capabilities, including fill/finish and labeling/packaging and as-needed distribution activities that could be readily repurposed for a pandemic influenza response. The goal of this project is to rapidly enable a mRNA-based national pandemic influenza vaccination response capability by generating manufacturing and clinical data with various influenza strains of pandemic potential.
Clinical Development and Manufacturing of mRNA-based Vaccines for Pandemic Preparedness
Project Details
Member Organization: ModernaTX, Inc.
Award Date: 06/28/2024
Award Amount: $176,000,000
Project Duration: 60
Solicitation Number: RRPV RPP-24-01-mRNA
Project Objective: ModernaTX will execute the regulatory, preclinical studies, clinical development and clinical studies, and CMC activities required to license a Group 1 H5NX subtype mRNA vaccine based on a highly pathogenic avian influenza A strain.
